NAT-ERIBULIN
Google image searchProduct monograph
Active ingredient
eribulin mesylate, 0.5 MG/ML
DIN: 02539136
Dosage form(s): SOLUTION
Route(s) of administration: INTRAVENOUS
Description: SINGLE USE
Schedule: Prescription
Company: NATCO PHARMA (CANADA) INC
Date: 08-JAN-2024
ATC:
- L01 — ANTINEOPLASTIC AGENTS (ATC, ATC/DDD, )
- L01X — OTHER ANTINEOPLASTIC AGENTS (ATC, ATC/DDD)
- L01XX — Other antineoplastic agents (ATC, ATC/DDD)
- L01XX41 — ERIBULIN (ATC/DDD)
Reference brand drug: Halaven
